Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aglatimagene besadenovec - Advantagene

Drug Profile

Aglatimagene besadenovec - Advantagene

Alternative Names: Adenovirus herpes simplex virus thymidine kinase gene therapy - Advantagene; AdV-Tk; AdV-tk therapy - Advantagene; ADV/HSV-tk; CanAtak; Cancer gene therapy - Advantagene; Gene Mediated Cytotoxic Immunotherapy; GliAtak; OncAtak; PancAtak; ProstAtak; TKR therapy - Advantagene; Virafir

Latest Information Update: 19 Jun 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Advantagene
  • Developer Advantagene; Baylor College of Medicine; Methodist Healthcare Ministries of South Texas
  • Class Antineoplastics; Gene therapies; Gene-directed enzyme-prodrug therapies
  • Mechanism of Action Thymidine kinase expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Brain cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase III Prostate cancer
  • Phase II Breast cancer; Glioma; Non-small cell lung cancer; Pancreatic cancer
  • Phase I/II Glioblastoma; Malignant pleural effusion; Ovarian cancer
  • Preclinical Mesothelioma; Oesophageal cancer

Most Recent Events

  • 17 Jun 2019 Advantagene completes enrollment in the phase II/III ULYSSES trial for Prostate cancer (Newly diagnosed) in Mexico and USA (Intratumoural) (NCT02768363)
  • 01 Apr 2019 Candel Therapeutics plans a pivotal trial for Glioma
  • 21 Mar 2019 Preliminary efficacy data from the phase II BrTK02 trial in Glioblastoma released by Candel Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top